Zobrazeno 1 - 10
of 97
pro vyhledávání: '"RICHARD A. HIIPAKKA"'
Autor:
Richard Baker Jones, Shutsung Liao, Richard A. Hiipakka, Ronald J. Hause, John M. Kokontis, Mark F. Ciaccio, Hui-Ping Lin, Chih-Pin Chuu
XLS file - 14K, This file contains data from the micro-western array protein analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3447330cfde1d6feeaf318ea4a56e36
https://doi.org/10.1158/1940-6207.22523425.v1
https://doi.org/10.1158/1940-6207.22523425.v1
Autor:
John M Kokontis, Hui-Ping Lin, Shih Sheng Jiang, Ching-Yu Lin, Junichi Fukuchi, Richard A Hiipakka, Chi-Jung Chung, Tzu-Min Chan, Shutsung Liao, Chung-Ho Chang, Chih-Pin Chuu
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109170 (2014)
The majority of prostate cancer (PCa) patient receiving androgen ablation therapy eventually develop castration-resistant prostate cancer (CRPC). We previously reported that androgen treatment suppresses Skp2 and c-Myc through androgen receptor (AR)
Externí odkaz:
https://doaj.org/article/630e19036e744c9a83ad7c2c060364e0
Autor:
Ching-Yu Lin, Chieh Huo, Li-Kuo Kuo, Richard A Hiipakka, Richard Baker Jones, Hui-Ping Lin, Yuwen Hung, Liang-Cheng Su, Jen-Chih Tseng, Ying-Yu Kuo, Yu-Ling Wang, Yasuhisa Fukui, Yung-Hsi Kao, John M Kokontis, Chien-Chih Yeh, Linyi Chen, Shiaw-Der Yang, Hsiao-Hui Fu, Ya-Wen Chen, Kelvin K C Tsai, Jang-Yang Chang, Chih-Pin Chuu
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e65734 (2013)
Oxysterols are oxidation products of cholesterol. Cholestane-3β, 5α, 6β-triol (abbreviated as triol) is one of the most abundant and active oxysterols. Here, we report that triol exhibits anti-cancer activity against human prostate cancer cells. T
Externí odkaz:
https://doaj.org/article/a2750f48587249f5af8b00ca39e2effd
Autor:
Richard A. Hiipakka, M Laine, Geoffrey L. Greene, Barry S. Komm, L Phung, Y-F Chang, M Greene
Publikováno v:
Cancer Research. 79:PD7-09
The standard of care for early postmenopausal ERα+ breast cancer patients is adjuvant endocrine therapy, typically an aromatase inhibitor or tamoxifen, and endocrine therapy with or without a CDK 4/6 inhibitor in the metastatic setting. However, a n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c08048a894249d61b0a75badf12cc05
https://doi.org/10.1158/1538-7445.sabcs18-pd7-09
https://doi.org/10.1158/1538-7445.sabcs18-pd7-09
Autor:
Geoffrey L. Greene, Richard A. Hiipakka, Marianne E. Greene, Ya-Fang Chang, Linda Phung, Barry S. Komm, Muriel Laine
Publikováno v:
Oncology Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3381830ffff839ef398afbe6f8a14b0
https://doi.org/10.1530/oncolabs.1.p024
https://doi.org/10.1530/oncolabs.1.p024
Autor:
Barry S. Komm, Muriel Laine, Sean W. Fanning, Linda Phung, Richard A. Hiipakka, Geoffrey L. Greene, Bradley Green, Ya-Fang Chang, Marianne E. Greene, Ross Han
Publikováno v:
Journal of the Endocrine Society
Activating somatic mutations to the ligand binding domain (LBD) of ESR1 (the gene for estrogen receptor alpha) may arise after prolonged hormone treatments. Y537S and D538G are the most prevalent mutations, accounting for 16% and 32% of cases respect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a36a5c368dfa81bb5e34d9873eb2565
https://doi.org/10.1210/js.2019-sun-006
https://doi.org/10.1210/js.2019-sun-006
Autor:
Ya-Fang Chang, Barry S. Komm, Marianne E. Greene, Richard A. Hiipakka, Geoffrey L. Greene, Sean W. Fanning, Linda Phung, Tina T Tan, Muriel Laine
Publikováno v:
Journal of Clinical Oncology. 37:1056-1056
1056 Background: Estrogen receptor positive (ER+) metastatic breast cancers (MBC) that express constitutively active somatic ESR1 mutations at Y537S and D538G allow tumors to progress in the presence of approved endocrine therapies. For patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf1a5a5582cae28ce519a84f84c82ecf
https://doi.org/10.1200/jco.2019.37.15_suppl.1056
https://doi.org/10.1200/jco.2019.37.15_suppl.1056
Autor:
Dacheng Peng, Qing Dai, Godfrey S. Getz, Shutsung Liao, Catherine A. Reardon, Jing-Tian Xie, John M. Kokontis, Richard A. Hiipakka
Publikováno v:
British Journal of Pharmacology. 162:1792-1804
BACKGROUND AND PURPOSE Potent synthetic nonsteroidal liver X receptor (LXR) agonists like T0901317 induce triglyceridaemia and fatty liver, effects not observed with some natural and synthetic steroidal, relatively weak agonists of LXR. To determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b21b2e426ff39d35863059d0510c6288
https://doi.org/10.1111/j.1476-5381.2011.01202.x
https://doi.org/10.1111/j.1476-5381.2011.01202.x
Autor:
Linda Phung, Marianne E. Greene, Ya-Fang Chang, Geoffrey L. Greene, Barry S. Komm, Richard A. Hiipakka, Muriel Laine
Publikováno v:
Journal of Clinical Oncology. 36:e13054-e13054
e13054Background: Postmenopausal ERα+ breast cancer patients are routinely treated with tamoxifen or an aromatase inhibitor as first line endocrine therapy. However, a number of patients that progr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f810724e3ad084951b249916772a591d
https://doi.org/10.1200/jco.2018.36.15_suppl.e13054
https://doi.org/10.1200/jco.2018.36.15_suppl.e13054
Autor:
Jing-Tian Xie, Godfrey S. Getz, Shutsung Liao, Catherine A. Reardon, Dacheng Peng, Richard A. Hiipakka
Publikováno v:
Atherosclerosis. 208:126-133
The effects of liver X receptor (LXR) agonists on plasma lipid homeostasis, especially triglyceride metabolism are controversial. Here we examined the effect of long-term activation of LXR on plasma lipid homeostasis in wild-type C57BL/6 and LDL rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c25fdc5d9af946f87cd28df2df406878
https://doi.org/10.1016/j.atherosclerosis.2009.07.016
https://doi.org/10.1016/j.atherosclerosis.2009.07.016